The DKTK EXLIQUID consortium – exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients

The DKTK EXLIQUID consortium – exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients

Testing for genetic alterations in tumor tissue allows clinicians to identify patients who most likely will benefit from molecular targeted treatment. EXLIQUID – exploiting liquid biopsies to advance cancer precision medicine – investigates the potential of additional non-invasive tools for guiding...

Full description

Bibliographic Details
Main Authors: Mack Matthias, Broche Julian, George Stephen, Hajjari Zahra, Janke Florian, Ranganathan Lavanya, Ashouri Mohammadreza, Bleul Sabine, Desuki Alexander, Engels Cecilia, Fliedner Stephanie M.J., Hartmann Nils, Hummel Michael, Janning Melanie, Kiel Alexander, Köhler Thomas, Koschade Sebastian, Lablans Martin, Lambarki Mohamed, Loges Sonja, Lueong Smiths, Meyer Sandra, Ossowski Stephan, Scherer Florian, Schroeder Christopher, Skowronek Patrick, Thiede Christian, Uhl Barbara, Vehreschild Jörg Janne, von Bubnoff Nikolas, Wagner Sebastian, Werner Tamara V., Westphalen C. Benedikt, Fresser Patrizia, Sültmann Holger, Tinhofer Ingeborg, Winter Christof
Format: Article
Language:English
Published: De Gruyter 2022-08-01
Series:Journal of Laboratory Medicine
Subjects:
liquid profiling
molecular profiling
precision oncology
Online Access:https://doi.org/10.1515/labmed-2022-0071

Internet

https://doi.org/10.1515/labmed-2022-0071

Similar Items